Monoclonal antibody · Antagonist of Insulin-like growth factor 1 receptor (IGF1R) · developed by Viridian Therapeutics
VRDN-003 is a subcutaneously administered, humanized monoclonal antibody that binds the insulin-like growth factor-1 receptor (IGF-1R). It is being studied in thyroid eye disease, a condition affecting the tissues around the eye.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06812325 | Phase 3 | Thyroid Eye Disease (TED) | Active not recruiting | VRDN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Thyroid Eye Disease (TED)
Updated Nov 1, 2026. Something wrong or missing? Report it on the VRDN page.
See VRDN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
VRDN catalysts and pipeline →